Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/13642
ชื่อเรื่อง: Investigation of therapeutic effects of α-mangostin on thioacetamide-induced cirrhosis in rats
ผู้แต่ง: Sukseree S.
Sophonnithiprasert T.
Pradidarcheep W.
Nilbunga S.
Nilwarangoon S.
Watanapokasin R.
Keywords: alanine aminotransferase
alpha mangostin
aspartate aminotransferase
beta actin
collagen type 1
inducible nitric oxide synthase
interleukin 1beta
plant medicinal product
protein p53
thioacetamide
tumor necrosis factor alpha
unclassified drug
alanine aminotransferase
aspartate aminotransferase
mangostin
thioacetamide
xanthone derivative
animal model
animal tissue
Article
chemoluminescence
controlled study
gene expression
gene sequence
liver cirrhosis
liver fibrosis
male
nonhuman
protein expression
rat
reverse transcription polymerase chain reaction
signal transduction
Western blotting
animal
blood
liver cirrhosis
Wistar rat
Alanine Transaminase
Animals
Aspartate Aminotransferases
Liver Cirrhosis
Male
Rats
Rats, Wistar
Thioacetamide
Xanthones
วันที่เผยแพร่: 2015
บทคัดย่อ: To determine the effects of alpha-mangostin on thioacetamide (TAA)-induced liver cirrhosis in rats. Material and Method: Male Wistar rats were divided into 3 groups and treated with intraperitoneal injections of TAA (200 mg/kg) 3 times per week for per week for 8, 12 and 16 weeks, respectively. One subgroup was left untreated whereas the other two were treated either with 100 mg/kg α-mangostin or vehicle alone (80% DMSO, 20% water), which were administered intraperitoneally 3 times per week for a total of 4 weeks. The incidence of fibrotic nodules on the liver and the serum levels of the liver enzymes aspartate transaminase (AST) and alanine transaminase (ALT) were measured. Moreover, the liver cirrhosis-related genes expression and p53 protein level in liver were analyzed by quantitative reverse transcription PCR and Western blot analysis, respectively. Results: Fibrotic nodules on the liver were formed upon treatment with TAA for 12 or 16 weeks. The nodules were then reduced by treatment with α-mangostin as compared to treatment with the vehicle DMSO. Moreover, the serum levels of the liver enzymes AST and ALT after treatment with α-mangostin decreased as compared to DMSO alone. The liver cirrhosisrelated genes expression showed no significant differences, whereas the p53 protein level in liver showed that α-mangostin reduced risk of liver fibrosis through the decrease in p53 expression as compared to the TAA_DMSO treatment. Conclusion: The results suggest that α-mangostin has a beneficial therapeutic effect in the TAA liver cirrhosis model. Further investigations on mechanisms of α-mangostin as therapeutic agent should be determined. © 2015, Medical Association of Thailand. All rights reserved.
URI: https://ir.swu.ac.th/jspui/handle/123456789/13642
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84957672524&partnerID=40&md5=af65bfe2cd12cffe62a520a1621bc8c7
ISSN: 1252208
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.